STOCK TITAN

ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
ADMA Biologics, Inc. will report second quarter financial results on August 9, 2023, after the U.S. financial markets close. A live conference call and audio webcast will be held at 4:30 p.m. ET on the same day to discuss the results and provide updates. Participants can register for the call to receive dial-in numbers and a unique PIN. The call will be available for replay on the Company's website.
Positive
  • None.
Negative
  • None.

Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics, today announced that it will report second quarter financial results on August 9, 2023, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call, participants may register for the call here to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call). A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789, among others, related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development & Corporate Strategy | 201-478-5552 | sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Jason Finkelstein
Managing Director, Argot Partners | 212-600-1902 | jason@argotpartners.com


FAQ

When will ADMA Biologics report its second quarter financial results?

ADMA Biologics will report its second quarter financial results on August 9, 2023, after the U.S. financial markets close.

What time is the conference call and audio webcast scheduled for?

The conference call and audio webcast are scheduled for 4:30 p.m. ET on August 9, 2023.

How can participants access the conference call?

Participants can register for the call to receive dial-in numbers and a unique PIN to access the call seamlessly.

Where can the audio webcast of the call be accessed?

The audio webcast of the call will be available under 'Events & Webcasts' in the investor section of the Company's website.

Will there be a replay of the conference call?

Yes, the conference call will be available for replay on the Company's website approximately two hours after the event.

ADMA Biologics, Inc.

NASDAQ:ADMA

ADMA Rankings

ADMA Latest News

ADMA Stock Data

2.43B
223.72M
2.59%
76.26%
3.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
RAMSEY

About ADMA

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.